NeoRx
This article was originally published in The Gray Sheet
Executive Summary
Oncto Trac lung cancer imaging product will be distributed in North America by DuPont Radiopharmaceuticals under an agreement announced Oct. 6. NeoRx will receive $2 mil. from DuPont Merck upon signing of the contract and an additional $4.5 mil. upon FDA approval of the small-cell lung cancer imaging kit, as well as product royalties. DuPont Merck will receive 269,000 shares of NeoRx common stock. The imaging kit, manufactured by Boehringer Ingelheim's wholly owned subsidiary Dr. Karl Thamae GmbH, is currently under review for final approval by FDA's Center for Biologics Evaluation and Research